We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lilly’s Once-Weekly Diabetes Drug Poses Challenge to Victoza’s Market Dominance
Lilly’s Once-Weekly Diabetes Drug Poses Challenge to Victoza’s Market Dominance
Preliminary data from a late-stage trial of Eli Lilly’s type 2 diabetes drug dulaglutide positions the candidate as a major contender in the increasingly competitive drug class known as GLP-1.